In late 2023, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) for sickle cell disease (SCD), marking the world ...

Next review: More evidence on exagamglogene autotemcel is being collected. After this, NICE will decide whether to recommend it for use in the NHS and update the guidance. It will be available with ...

when a haematopoietic stem cell transplant (a blood and marrow transplant) is suitable, but a human leukocyte antigen-matched related haematopoietic stem cell donor is not available. It is only ...

The reality of an approved CRISPR treatment arrived at the end of 2023, with CRISPR Therapeutics and Vertex’s Casgevy (exagamglogene autotemcel) receiving the FDA’s nod for the treatment of ...

The Indiana-based drugmaker is slashing the prices of its 2.5 mg single-dose vials to $349 per month and bringing its 5 mg single-dose vials down to $499 per month, it said in a Tuesday press release.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A bunch of people I know (including me) have gotten sick ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from ...

Casgevy and Lyfgenia, the two cell-based gene therapies approved by the FDA, utilise the CRISPR/Cas9 genome editing technology. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR ...

The biotech's Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals, is now approved in the U.S ...